The Family Firm’s Gilead Sciences GILD Stock Holding History

The Family Firm’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-947	Closed	-$65K	–	452
2024 Q2	$65K	Buy	+947	New	+$63.2K	0.01%	352

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

The Family Firm's GILD Position: Q3 2024 in Review

The Family Firm sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 947 shares — an estimated $65K sold.

The Family Firm first reported a position in GILD in Q2 2024 and held it in 1 quarter. The position peaked at $65K in Q2 2024. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

The Family Firm reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 947 Gilead Sciences shares in Q3 2024, an estimated $65K.
The Family Firm first reported a position in Gilead Sciences in Q2 2024 and held it in 1 quarter.
The Family Firm's Gilead Sciences position peaked at $65K in Q2 2024.
1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.